DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global COPD & Asthma Devices Market (2016-2022)" report to their offering.
The global asthma and COPD drug market is a multi-billion dollar market which has a history of several decades and has witnessed number of technological advancements and product development over the past few years. Growing aging population coupled with increasing automotive and industrial exhaust gases have remained the key drivers for the global asthma and COPD market.
Degrading air quality near the industrial areas has led to the increased incidence of asthma especially in the low-income population in the emerging economies of China, India, Brazil and Russia. Increasing disposable income levels in emerging economies as well as developing countries of Latin America, Middle East & Africa has led to the increased usage of asthma pumps and sprays in these regions.
However, the unknown etiology of asthma and COPD in medical industry may hamper the market growth in the next six years. Upcoming treatment methodologies such as once-a-day combination products and monoclonal antibodies have created new opportunities for the market growth. Additionally, pharmaceutical companies have been developing new bio-based medications in combination with bio-technology which promises immense growth opportunities along with sustainable development for asthma & COPD market over the next decade.
Companies Mentioned:
- Glaxosmithkline PLC
- Novartis International AG
- Merck & Co., Inc.
- AstraZeneca Plc
- 3M Healthcare
- GF Health Products, Inc
- Sunovion Pharmaceuticals Inc.
- Koninklijke Philips N.V.
- Smith Medicals, Inc.
-
Baxter International
Key Topics Covered:
1. Market Scope & Methodology
2. Global COPD and Asthma Devices Market Overview
3. Global COPD and Asthma Device Market - By Product Type
4. Global COPD & Asthma Devices Market - By Geography
5. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/wrlbg5/global_copd_and
